News Releases

June 16, 2022
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass. and BOULDER, Colo., June 16, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its upsized underwritten public offering of 17,899,698
June 13, 2022
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants
CAMBRIDGE, Mass. and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of an underwritten public offering of 15,169,698 shares of
June 13, 2022
Cogent Biosciences Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $125 million
June 10, 2022
Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
All patients treated with bezuclastinib achieved ≥ 50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment All bone marrow biopsy-assessed patients achieved ≥ 50% bone marrow mast cell reduction and decreases in blood KIT D816V variant
June 6, 2022
Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET
– Event to review initial clinical data from APEX, a Phase 2 trial with bezuclastinib in Advanced Systemic Mastocytosis presented at European Hematology Association (EHA) Congress CAMBRIDGE, Mass. and BOULDER, Colo., June 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.
June 2, 2022
Cogent Biosciences Announces Annual Meeting of Stockholders
CAMBRIDGE, Mass. and BOULDER, Colo., June 02, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the Annual Meeting of Stockholders will take place virtually on June
May 12, 2022
Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress
Poster to highlight initial data from on-going Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) CAMBRIDGE, Mass. and BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on
May 10, 2022
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results
Initial bezuclastinib APEX data to be presented at the European Hematology Association (EHA) 2022 Annual Congress Building a portfolio of discovery stage programs, creating potential best-in-class small molecule kinase inhibitors for genetically defined oncology indications and rare diseases Ended
May 6, 2022
Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium
CAMBRIDGE, Mass. and BOULDER, Colo., May 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that management will participate in a fireside chat at the LifeSci
April 11, 2022
Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event
New bezuclastinib nonclinical data demonstrate superior selectivity against closely related kinases, as well as minimal brain penetration, compared with other KIT inhibitors  Building a pipeline of multiple small molecule inhibitors targeting genetically defined diseases, including next generation
Displaying 1 - 10 of 15
The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.